Movement Alert｜WuXi XDC Falls 3.14% in Regular Trading, Intensive Buybacks Fail to Reverse Persistent Sector Selling Pressure

Market Focus05-28

On May 28, WuXi XDC declined 3.14% in regular trading to HK$55.4 per share, with turnover of approximately HK$28.93 million, marking consecutive sessions of weakness.

On the news front, the company previously announced plans to deploy up to US$100 million in internal funds for open-market share repurchases, while parent company WuXi Biologics also unveiled a buyback plan of up to US$400 million, bringing the combined repurchase scale to US$500 million. However, the intensive buyback programs have failed to effectively restore market confidence. The broader WuXi family of stocks remained under significant pressure, with WuXi AppTec down 3.44% and WuXi Biologics down 2.91% in the same session.

Guotai Junan International maintains an Overweight rating on the company with a target price of HK$84.38, citing optimism on ADC pipeline growth prospects. The company reported backlog orders of approximately US$1.489 billion, up 50.3% year-over-year, with new contract value of US$1.33 billion, up 41% year-over-year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1166527949?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 09:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1166527949","market":"us","top_or_hot":-1,"title":"Movement Alert｜WuXi XDC Falls 3.14% in Regular Trading, Intensive Buybacks Fail to Reverse Persistent Sector Selling Pressure","media":"Market Focus","content":"<p><p>On May 28, WuXi XDC declined 3.14% in regular trading to HK$55.4 per share, with turnover of approximately HK$28.93 million, marking consecutive sessions of weakness.</p><p>On the news front, the company previously announced plans to deploy up to US$100 million in internal funds for open-market share repurchases, while parent company WuXi Biologics also unveiled a buyback plan of up to US$400 million, bringing the combined repurchase scale to US$500 million. However, the intensive buyback programs have failed to effectively restore market confidence. The broader WuXi family of stocks remained under significant pressure, with WuXi AppTec down 3.44% and WuXi Biologics down 2.91% in the same session.</p><p>Guotai Junan International maintains an Overweight rating on the company with a target price of HK$84.38, citing optimism on ADC pipeline growth prospects. The company reported backlog orders of approximately US$1.489 billion, up 50.3% year-over-year, with new contract value of US$1.33 billion, up 41% year-over-year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi XDC Falls 3.14% in Regular Trading, Intensive Buybacks Fail to Reverse Persistent Sector Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi XDC Falls 3.14% in Regular Trading, Intensive Buybacks Fail to Reverse Persistent Sector Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 09:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, WuXi XDC declined 3.14% in regular trading to HK$55.4 per share, with turnover of approximately HK$28.93 million, marking consecutive sessions of weakness.</p><p>On the news front, the company previously announced plans to deploy up to US$100 million in internal funds for open-market share repurchases, while parent company WuXi Biologics also unveiled a buyback plan of up to US$400 million, bringing the combined repurchase scale to US$500 million. However, the intensive buyback programs have failed to effectively restore market confidence. The broader WuXi family of stocks remained under significant pressure, with WuXi AppTec down 3.44% and WuXi Biologics down 2.91% in the same session.</p><p>Guotai Junan International maintains an Overweight rating on the company with a target price of HK$84.38, citing optimism on ADC pipeline growth prospects. The company reported backlog orders of approximately US$1.489 billion, up 50.3% year-over-year, with new contract value of US$1.33 billion, up 41% year-over-year.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02268","symbol_name":"药明合联","start_time":0,"source_url":"","article_id":"1166527949","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1166527949","pubTimestamp":1779932843,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, WuXi XDC declined 3.14% in regular trading to HK$55.4 per share, with turnover of approximately HK$28.93 million, marking consecutive sessions of weakness.On the news front, the company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02268":"药明合联"},"translate_title":"动向提示|药明XDC常规交易跌3.14%密集回购未能扭转持续板块抛压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02268":1},"content_text":"On May 28, WuXi XDC declined 3.14% in regular trading to HK$55.4 per share, with turnover of approximately HK$28.93 million, marking consecutive sessions of weakness.On the news front, the company previously announced plans to deploy up to US$100 million in internal funds for open-market share repurchases, while parent company WuXi Biologics also unveiled a buyback plan of up to US$400 million, bringing the combined repurchase scale to US$500 million. However, the intensive buyback programs have failed to effectively restore market confidence. The broader WuXi family of stocks remained under significant pressure, with WuXi AppTec down 3.44% and WuXi Biologics down 2.91% in the same session.Guotai Junan International maintains an Overweight rating on the company with a target price of HK$84.38, citing optimism on ADC pipeline growth prospects. The company reported backlog orders of approximately US$1.489 billion, up 50.3% year-over-year, with new contract value of US$1.33 billion, up 41% year-over-year.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1166527949","isCrawlerRequest":true}